|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TGFB1 |
Gene summary for TGFB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TGFB1 | Gene ID | 7040 |
| Gene name | transforming growth factor beta 1 | |
| Gene Alias | CED | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0000018 | UniProtAcc | P01137 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7040 | TGFB1 | LZE4T | Human | Esophagus | ESCC | 1.43e-05 | 2.58e-01 | 0.0811 |
| 7040 | TGFB1 | LZE20T | Human | Esophagus | ESCC | 6.37e-06 | 3.69e-01 | 0.0662 |
| 7040 | TGFB1 | LZE22D1 | Human | Esophagus | HGIN | 1.14e-03 | 1.78e-01 | 0.0595 |
| 7040 | TGFB1 | LZE22T | Human | Esophagus | ESCC | 3.87e-10 | 7.23e-01 | 0.068 |
| 7040 | TGFB1 | LZE24T | Human | Esophagus | ESCC | 2.12e-38 | 1.17e+00 | 0.0596 |
| 7040 | TGFB1 | LZE21T | Human | Esophagus | ESCC | 9.25e-05 | 5.08e-01 | 0.0655 |
| 7040 | TGFB1 | P1T-E | Human | Esophagus | ESCC | 4.83e-08 | 6.50e-01 | 0.0875 |
| 7040 | TGFB1 | P2T-E | Human | Esophagus | ESCC | 5.15e-08 | 1.12e-01 | 0.1177 |
| 7040 | TGFB1 | P4T-E | Human | Esophagus | ESCC | 9.88e-33 | 7.78e-01 | 0.1323 |
| 7040 | TGFB1 | P5T-E | Human | Esophagus | ESCC | 4.15e-27 | 5.74e-01 | 0.1327 |
| 7040 | TGFB1 | P8T-E | Human | Esophagus | ESCC | 9.16e-24 | 5.53e-01 | 0.0889 |
| 7040 | TGFB1 | P9T-E | Human | Esophagus | ESCC | 4.33e-12 | 3.66e-01 | 0.1131 |
| 7040 | TGFB1 | P10T-E | Human | Esophagus | ESCC | 2.54e-21 | 4.23e-01 | 0.116 |
| 7040 | TGFB1 | P11T-E | Human | Esophagus | ESCC | 1.78e-27 | 1.14e+00 | 0.1426 |
| 7040 | TGFB1 | P12T-E | Human | Esophagus | ESCC | 1.01e-20 | 4.48e-01 | 0.1122 |
| 7040 | TGFB1 | P15T-E | Human | Esophagus | ESCC | 2.41e-37 | 7.87e-01 | 0.1149 |
| 7040 | TGFB1 | P16T-E | Human | Esophagus | ESCC | 1.21e-04 | 1.65e-01 | 0.1153 |
| 7040 | TGFB1 | P17T-E | Human | Esophagus | ESCC | 8.42e-19 | 8.11e-01 | 0.1278 |
| 7040 | TGFB1 | P19T-E | Human | Esophagus | ESCC | 2.47e-04 | 4.32e-01 | 0.1662 |
| 7040 | TGFB1 | P20T-E | Human | Esophagus | ESCC | 3.03e-33 | 7.74e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004603427 | Esophagus | HGIN | ATP metabolic process | 101/2587 | 277/18723 | 1.53e-21 | 1.02e-18 | 101 |
| GO:007259420 | Esophagus | HGIN | establishment of protein localization to organelle | 120/2587 | 422/18723 | 1.73e-15 | 4.00e-13 | 120 |
| GO:003450417 | Esophagus | HGIN | protein localization to nucleus | 84/2587 | 290/18723 | 1.06e-11 | 1.24e-09 | 84 |
| GO:000691319 | Esophagus | HGIN | nucleocytoplasmic transport | 83/2587 | 301/18723 | 2.14e-10 | 1.97e-08 | 83 |
| GO:005116919 | Esophagus | HGIN | nuclear transport | 83/2587 | 301/18723 | 2.14e-10 | 1.97e-08 | 83 |
| GO:000914419 | Esophagus | HGIN | purine nucleoside triphosphate metabolic process | 36/2587 | 88/18723 | 3.49e-10 | 3.05e-08 | 36 |
| GO:000914518 | Esophagus | HGIN | purine nucleoside triphosphate biosynthetic process | 31/2587 | 69/18723 | 3.51e-10 | 3.05e-08 | 31 |
| GO:000920618 | Esophagus | HGIN | purine ribonucleoside triphosphate biosynthetic process | 30/2587 | 68/18723 | 1.16e-09 | 9.27e-08 | 30 |
| GO:000920518 | Esophagus | HGIN | purine ribonucleoside triphosphate metabolic process | 33/2587 | 82/18723 | 3.10e-09 | 2.27e-07 | 33 |
| GO:190382926 | Esophagus | HGIN | positive regulation of cellular protein localization | 75/2587 | 276/18723 | 3.19e-09 | 2.30e-07 | 75 |
| GO:000675417 | Esophagus | HGIN | ATP biosynthetic process | 26/2587 | 57/18723 | 6.19e-09 | 4.04e-07 | 26 |
| GO:000920117 | Esophagus | HGIN | ribonucleoside triphosphate biosynthetic process | 30/2587 | 74/18723 | 1.30e-08 | 8.15e-07 | 30 |
| GO:000914120 | Esophagus | HGIN | nucleoside triphosphate metabolic process | 39/2587 | 112/18723 | 1.56e-08 | 9.53e-07 | 39 |
| GO:005116819 | Esophagus | HGIN | nuclear export | 48/2587 | 154/18723 | 2.21e-08 | 1.34e-06 | 48 |
| GO:000919917 | Esophagus | HGIN | ribonucleoside triphosphate metabolic process | 33/2587 | 89/18723 | 3.42e-08 | 1.97e-06 | 33 |
| GO:000914218 | Esophagus | HGIN | nucleoside triphosphate biosynthetic process | 32/2587 | 85/18723 | 3.61e-08 | 2.04e-06 | 32 |
| GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
| GO:004682219 | Esophagus | HGIN | regulation of nucleocytoplasmic transport | 35/2587 | 106/18723 | 3.69e-07 | 1.69e-05 | 35 |
| GO:003133425 | Esophagus | HGIN | positive regulation of protein-containing complex assembly | 61/2587 | 237/18723 | 7.10e-07 | 3.00e-05 | 61 |
| GO:190018216 | Esophagus | HGIN | positive regulation of protein localization to nucleus | 30/2587 | 87/18723 | 8.74e-07 | 3.59e-05 | 30 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0522041 | Oral cavity | EOLP | Chronic myeloid leukemia | 24/1218 | 76/8465 | 1.01e-04 | 4.48e-04 | 2.64e-04 | 24 |
| hsa0514221 | Oral cavity | EOLP | Chagas disease | 28/1218 | 102/8465 | 4.05e-04 | 1.64e-03 | 9.65e-04 | 28 |
| hsa0435022 | Oral cavity | EOLP | TGF-beta signaling pathway | 29/1218 | 108/8465 | 4.81e-04 | 1.92e-03 | 1.13e-03 | 29 |
| hsa0493341 | Oral cavity | EOLP | AGE-RAGE signaling pathway in diabetic complications | 27/1218 | 100/8465 | 6.77e-04 | 2.63e-03 | 1.55e-03 | 27 |
| hsa0522523 | Oral cavity | EOLP | Hepatocellular carcinoma | 39/1218 | 168/8465 | 1.35e-03 | 4.80e-03 | 2.83e-03 | 39 |
| hsa0514623 | Oral cavity | EOLP | Amoebiasis | 26/1218 | 102/8465 | 2.09e-03 | 7.03e-03 | 4.15e-03 | 26 |
| hsa0492622 | Oral cavity | EOLP | Relaxin signaling pathway | 30/1218 | 129/8465 | 4.48e-03 | 1.42e-02 | 8.37e-03 | 30 |
| hsa0406823 | Oral cavity | EOLP | FoxO signaling pathway | 29/1218 | 131/8465 | 1.05e-02 | 2.85e-02 | 1.68e-02 | 29 |
| hsa0541555 | Oral cavity | EOLP | Diabetic cardiomyopathy | 64/1218 | 203/8465 | 2.48e-10 | 1.00e-08 | 5.91e-09 | 64 |
| hsa0465933 | Oral cavity | EOLP | Th17 cell differentiation | 41/1218 | 108/8465 | 9.84e-10 | 3.18e-08 | 1.87e-08 | 41 |
| hsa0493255 | Oral cavity | EOLP | Non-alcoholic fatty liver disease | 51/1218 | 155/8465 | 3.32e-09 | 6.74e-08 | 3.98e-08 | 51 |
| hsa0514552 | Oral cavity | EOLP | Toxoplasmosis | 41/1218 | 112/8465 | 3.50e-09 | 6.74e-08 | 3.98e-08 | 41 |
| hsa043803 | Oral cavity | EOLP | Osteoclast differentiation | 44/1218 | 128/8465 | 8.92e-09 | 1.37e-07 | 8.10e-08 | 44 |
| hsa0421855 | Oral cavity | EOLP | Cellular senescence | 50/1218 | 156/8465 | 1.27e-08 | 1.83e-07 | 1.08e-07 | 50 |
| hsa0516654 | Oral cavity | EOLP | Human T-cell leukemia virus 1 infection | 64/1218 | 222/8465 | 1.37e-08 | 1.83e-07 | 1.08e-07 | 64 |
| hsa051615 | Oral cavity | EOLP | Hepatitis B | 49/1218 | 162/8465 | 1.38e-07 | 1.54e-06 | 9.07e-07 | 49 |
| hsa0521251 | Oral cavity | EOLP | Pancreatic cancer | 27/1218 | 76/8465 | 3.23e-06 | 2.32e-05 | 1.37e-05 | 27 |
| hsa0521052 | Oral cavity | EOLP | Colorectal cancer | 29/1218 | 86/8465 | 4.71e-06 | 3.17e-05 | 1.87e-05 | 29 |
| hsa0520553 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
| hsa0515251 | Oral cavity | EOLP | Tuberculosis | 47/1218 | 180/8465 | 2.19e-05 | 1.18e-04 | 6.96e-05 | 47 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | ADJ |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | DCIS |
| TGFB1 | ACVR1_TGFbR | TGFB1_ACVR1_TGFBR1 | TGFb | Breast | DCIS |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Breast | IDC |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Cervix | CC |
| TGFB1 | ACVR1_TGFbR | TGFB1_ACVR1_TGFBR1 | TGFb | Cervix | CC |
| TGFB1 | ACVR1B_TGFbR2 | TGFB1_ACVR1B_TGFBR2 | TGFb | CRC | AD |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | CRC |
| TGFB1 | ACVR1B_TGFbR2 | TGFB1_ACVR1B_TGFBR2 | TGFb | CRC | CRC |
| TGFB1 | ACVR1C_TGFbR2 | TGFB1_ACVR1C_TGFBR2 | TGFb | CRC | CRC |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | MSI-H |
| TGFB1 | ACVR1B_TGFbR2 | TGFB1_ACVR1B_TGFBR2 | TGFb | CRC | MSI-H |
| TGFB1 | ACVR1_TGFbR | TGFB1_ACVR1_TGFBR1 | TGFb | CRC | MSI-H |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | CRC | SER |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Endometrium | ADJ |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Endometrium | AEH |
| TGFB1 | ACVR1B_TGFbR2 | TGFB1_ACVR1B_TGFBR2 | TGFb | Endometrium | AEH |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | Esophagus | ESCC |
| TGFB1 | ACVR1_TGFbR | TGFB1_ACVR1_TGFBR1 | TGFb | Esophagus | ESCC |
| TGFB1 | TGFbR1_R2 | TGFB1_TGFBR1_TGFBR2 | TGFb | HNSCC | ADJ |
| Page: 1 2 3 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TGFB1 | SNV | Missense_Mutation | novel | c.1079N>T | p.Ala360Val | p.A360V | P01137 | protein_coding | tolerated(0.75) | benign(0.001) | TCGA-3C-AAAU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | zoladex | SD |
| TGFB1 | SNV | Missense_Mutation | c.1031A>T | p.Asn344Ile | p.N344I | P01137 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A1AR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Docetaxel | PD | |
| TGFB1 | SNV | Missense_Mutation | c.368N>T | p.Lys123Met | p.K123M | P01137 | protein_coding | tolerated(0.12) | possibly_damaging(0.45) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TGFB1 | SNV | Missense_Mutation | c.1099N>A | p.Val367Met | p.V367M | P01137 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TGFB1 | SNV | Missense_Mutation | c.829N>T | p.Arg277Cys | p.R277C | P01137 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TGFB1 | SNV | Missense_Mutation | c.727N>A | p.Arg243Ser | p.R243S | P01137 | protein_coding | tolerated(0.77) | benign(0.428) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TGFB1 | SNV | Missense_Mutation | rs142642007 | c.442N>A | p.Val148Met | p.V148M | P01137 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-SS-A7HO-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | oxaliplatin | PD |
| TGFB1 | SNV | Missense_Mutation | c.883N>A | p.Val295Met | p.V295M | P01137 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AH-6544-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| TGFB1 | SNV | Missense_Mutation | rs201327622 | c.661G>A | p.Ala221Thr | p.A221T | P01137 | protein_coding | tolerated(0.17) | benign(0.034) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TGFB1 | SNV | Missense_Mutation | c.248N>T | p.Ser83Ile | p.S83I | P01137 | protein_coding | deleterious(0) | possibly_damaging(0.706) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | Disitertide | DISITERTIDE | 24393789 | |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | ANTIOXIDANT | 12221586 | ||
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | Pirfenidone | PIRFENIDONE | ||
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | VERAPAMIL | VERAPAMIL | ||
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | TOREMIFENE | TOREMIFENE | 12476040 | |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | TAMOXIFEN | TAMOXIFEN | 8019941 | |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | BRDU | 10495776 | ||
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | PIRFENIDONE | PIRFENIDONE | 12907346 | |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | TRIAMCINOLONE | TRIAMCINOLONE | 12174062 | |
| 7040 | TGFB1 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | BOVINE CARTILAGE | 12525389 |
| Page: 1 2 3 4 5 6 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |